Figure 7

Neutralizing FGF-2 antibody blocks SC proliferation and survival induced by BMMC-CM in vitro. A-E: ST-8814 SCs cultured for 48 h in low density (2.00 x 104 cells/well) with DMEM F-12 + 10% FBS (A), CM (B), CM+ neutralizing FGF-2 antibody (C), rhFGF-2 (D) or rhFGF-2 + neutralizing FGF-2 antibody (E). Cells were immunolabeled for KI-67 and cell nuclei were counterstained with DAPI. F: Quantification of the percentage of KI-67+ SC per mm2. Statistics: p<0.0001 ANOVA. G and H: Western blotting and quantitative analysis of the active Akt (p-Akt, G) and active ERK 1/2 (p-ERK 1/2, H) from SCs cultured for 48 h with control medium, CM, CM+ neutralizing FGF-2, rhFGF-2 + neutralizing FGF-2 or rhFGF-2. I: Semi quantitative polymerase chain reaction (RT-PCR) for FGF-2 transcripts from samples of BMMC or MSC in the presence or absence of sciatic nerve pieces. Quantitative analysis showing the transcript level following the same experimental conditions. Statistics: p<0.0001 ANOVA. Scale bar: A-E=50 µm.